FIELD: medicine, immunology.
SUBSTANCE: invention relates to methods for inducing of prolonged immune response in patients with reduced immunity. Claimed methods include application of enkephaline peptides which are administered according to initial dosage pattern with interruption for at least 4 weeks followed by transition to supporting doses.
EFFECT: prolonged and effective increasing of T-cell levels in patients with reduced immunity.
5 tbl, 2 ex, 14 cl
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOGENS FOR VACCINATION AGAINST HIV | 2013 |
|
RU2721274C2 |
| DERIVATIVES OF PROTEIN FUSED WITH Fc WITH HIGH DOUBLE ACTIVITY: ANTIVIRAL ACTIVITY RELATIVELY TO HIV AND IMMUNOMODULATING ACTIVITY | 2018 |
|
RU2774782C2 |
| METHODS AND COMPOSITION FOR INHIBITION OF HIV-1 MULTIPLICATION | 2001 |
|
RU2275379C2 |
| VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCTION OF ANTIBODY EXPRESSION | 2017 |
|
RU2813282C2 |
| MULTIVALENT IMMUNOTHERAPEUTIC COMBINATION AND METHODS OF USE FOR TREATING WT1-POSITIVE CANCERS | 2020 |
|
RU2827874C2 |
| TREATMENT AND FUNCTIONAL CURE OF HIV-INFECTION WITH MONOCLONAL ANTIBODIES TO CD4 MEDIATING COMPETITIVE INHIBITION OF HIV ENTRY | 2014 |
|
RU2762315C2 |
| HIV ANTIBODY COMPOSITIONS AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2757135C2 |
| PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY | 2008 |
|
RU2523894C2 |
| STABLE FORMULATIONS OF ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 AND RELATED TREATMENT METHODS | 2012 |
|
RU2563346C2 |
| COMPOSITIONS OF ANTI-CD6 ANTIBODIES AND METHODS OF TREATING AND REDUCING NEGATIVE CONSEQUENCES OF CORONAVIRUS, INCLUDING COVID-19 | 2021 |
|
RU2828013C1 |
